Gilead Sciences Inc Stock (GILD) Closed Up by 3.04% on May 22: Drivers Behind the Movement
Gilead Sciences Inc. (GILD) stock closed up by 3.04% on May 22, outperforming its sector, driven primarily by significant advancements in its product pipeline and regulatory milestones. Key drivers include the FDA approval of Hepcludex for chronic hepatitis delta virus infection and the European Medicines Agency's positive recommendation for Trodelvy in advanced breast cancer. Despite some reports of insider selling and a lowered Q4 2026 EPS estimate, these positive developments provided a strong catalyst for the stock's upward movement.
3 Stocks Estimated To Be Trading Below Their Intrinsic Value By Up To 42.4%
This article identifies three U.S. stocks—Prosperity Bancshares (PB), Pinnacle Financial Partners (PNFP), and Victoria's Secret (VSCO)—that are estimated to be trading significantly below their intrinsic value based on discounted cash flow analysis, despite some having recent challenges like insider selling or high debt. It highlights their potential for growth, with earnings projections often exceeding market averages, and encourages investors to further investigate these opportunities.
Stocks making the biggest moves midday: Dell Technologies, HP, Estee Lauder, Generac & more
This article details the midday stock movements of several companies, including Dell Technologies and HP, which rose after a strong report from competitor Lenovo. Estee Lauder and Workday also saw gains, while Chinese operations like Futu and PDD Holdings dropped due to a crackdown on illegal cross-border securities trading. Generac's stock increased following an upgrade from Jefferies due to the data center buildout.
AbbVie, Merck, Astra among winners of EU drug recommendations this week
The EU drug regulator's expert panel has recommended eight new medicines for approval this week, benefiting companies like Merck, AstraZeneca, and AbbVie. Merck's Keytruda, AstraZeneca's Enhertu, and AbbVie's Maviret received positive opinions for new indications, suggesting expanded market access and potential revenue growth. Pending final decisions from the European Commission could significantly impact the future revenue streams for these drugmakers by unlocking new sales volumes for larger or new patient groups.
Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026
Crescent Biopharma (CBIO) has not yet received any FDA approvals for its therapy CR-001, which is being investigated for the treatment of advanced solid tumors. The company recently announced a poster presentation for its ASCEND study of CR-001 at the 2026 ASCO Annual Meeting and previously reported dosing the first patient in its global Phase 1/2 clinical trial for the drug. Crescent Biopharma anticipates multiple data readouts for CR-001 starting in Q1 2027.
Merck & Co Inc Stock (MRK) Opened Up by 4.50% on May 22: Facts Behind the Movement
Merck & Co Inc (MRK) saw its stock open up by 4.50% on May 22, driven primarily by positive Phase III clinical trial results for its sacituzumab tirumotecan (sac-TMT) in combination with Keytruda for lung cancer. Upcoming extensive oncology data presentations at the ASCO meeting and strong Q1 2026 earnings that surpassed expectations further contributed to the optimistic investor sentiment. Despite recent setbacks like a failed trial and a downgrade from one analyst, the company's financial performance and strategic pipeline developments are buoying its stock price.
Merck & Co., Inc. stock (US58933Y1055): Key cancer drug data and dividend profile in focus
Merck & Co., Inc. is gaining attention for its strong oncology data, particularly concerning its blockbuster cancer therapy Keytruda, and its consistent dividend payouts. The article details Merck's business model, emphasizing its focus on R&D, product diversification, and robust financial profile, while also noting the risks associated with its reliance on Keytruda. Key updates on its pipeline and significance for US investors are also highlighted.
Merck and Kelun's lung cancer combo bests Keytruda (MRK:NYSE)
A collaboration between Merck and Chinese biopharma company Kelun-Biotech has yielded promising results from a late-stage trial for lung cancer. Their antibody drug conjugate, when used with Keytruda, demonstrated superior performance compared to Keytruda alone. This development could represent a significant advancement in lung cancer treatment.
Keudell Morrison Wealth Management Invests $1.33 Million in Merck & Co., Inc. $MRK
Keudell Morrison Wealth Management recently invested $1.33 million in Merck & Co., Inc. (NYSE:MRK), purchasing 12,657 shares in the fourth quarter. The pharmaceutical giant has shown positive operating and pipeline updates, including beating earnings estimates and promising results from oncology trials. Despite some neutral and negative sentiments from analysts, Merck maintains a "Moderate Buy" rating with an average price target of $128.18.
Moderna, Merck cancer combo cuts melanoma spread risk at five years
A combination therapy by Moderna and Merck for skin cancer has shown a significant reduction in the risk of cancer spreading, according to mid-stage trial data. The therapy, which combines Moderna's personalized cancer vaccine intismeran autogene with Merck's Keytruda immunotherapy, reduced the risk of melanoma spreading by 59% after five years of follow-up. The results also indicated a 92.2% overall survival rate for the combination arm, compared to 71.3% for the Keytruda-alone group.
Amgen CFO Change Puts Focus On Debt, Growth And Capital Discipline
Amgen has announced that its long-serving CFO, Peter Griffith, will retire, with Thomas Dittrich appointed as his successor, effective September 1, 2026. This transition is significant for investors, as the new CFO's approach to capital allocation and debt management will be crucial, especially given Amgen's current debt levels and ongoing regulatory scrutiny for certain products. The extended handover period until January 2027 suggests a smooth transition, but investors will be closely watching for shifts in the company's financial discipline and communication regarding growth and spending.
Merck (MRK) – Expands Oncology Leadership with New Clinical Data at ASCO 2026
Merck announced it will present over 100 abstracts at the 2026 ASCO Annual Meeting, showcasing new clinical data for KEYTRUDA and other oncology pipeline programs. The presentations will highlight progress in personalized cancer vaccines, combination immunotherapies, and ADCs, reinforcing Merck's leadership in oncology and its strategy to diversify beyond KEYTRUDA. This strategic move aims to strengthen its position as KEYTRUDA approaches patent exclusivity challenges.
Merck & Co., Inc. Balance Sheet – BVL:MRKUS
Merck & Co., Inc. (BVL:MRKUS) reported its Q1 2026 financial position, showing total assets at 450.45 billion PEN, a 2.20% decrease from Q4 2025. Concurrently, total liabilities for the pharmaceutical company increased by 2.22% to 289.67 billion PEN in the same quarter. The article provides a historical overview of the company's balance sheet data from 2006, highlighting key financial metrics such as total assets, total liabilities, total equity, and total debt.
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
Agenus (AGEN) shares have dropped 19.4% in the last month following disappointing Q1 2026 results. The company's primary growth driver is its immuno-oncology combination, BOT/BAL, which is progressing through phase III trials and expanding access internationally. Despite promising pipeline advancements, Agenus faces significant competition from larger pharmaceutical companies, leading to a "Hold" rating from Zacks Investment Research.
How Investors May Respond To Exelixis (EXEL) Merck MRD+ Colorectal Cancer Trial Collaboration
Exelixis recently announced a clinical development collaboration with Merck for the STELLAR-316 trial, testing zanzalintinib with KEYTRUDA QLEX in MRD+ colorectal cancer patients. This partnership aims to diversify Exelixis's revenue beyond CABOMETYX and strengthens the investment narrative, though concerns about CABOMETYX concentration and discount pressure remain. The article suggests investors should consider the broader potential of zanzalintinib, including its FDA review in metastatic colorectal cancer, against more pessimistic analyst forecasts.
Merck & Co., Inc. stock (US58933Y1055): cancer franchise drives outlook after latest Keytruda data
Merck & Co., Inc. has highlighted new clinical data for its cancer drug Keytruda and provided updates on its late-stage pipeline, reinforcing growth expectations despite future patent expiries. The company positions itself as a leading oncology and vaccines player, with Keytruda remaining its dominant revenue driver and vaccines contributing stable growth. Merck's strategy involves sustained R&D investment, strategic collaborations, and diversification across therapeutic areas to mitigate competitive and regulatory pressures.
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and Pfizer - Global Forecast to 2030 and 2035
The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market is projected to grow from $15.5 billion in 2025 to $18.02 billion in 2026, reaching $32.87 billion by 2030, driven by rising obesity rates, new drug approvals like Eli Lilly's Zepbound, and increased insurance coverage. Key players include Novo Nordisk A/S, Eli Lilly and Company, and Pfizer Inc. While tariffs pose cost challenges, they also encourage domestic production, contributing to the market's robust growth trajectory and innovation in therapies beyond diabetes management.
AstraZeneca PLC stock (US6549022043): analysts update views as pipeline news keeps investors alert
AstraZeneca PLC (US6549022043) remains a focus for investors in May 2026 due to updated analyst commentary and new pipeline developments, particularly in its respiratory portfolio. Analysts see a moderate upside potential for the stock, with an average 12-month price target of USD 205.33, implying differing views on the company's future growth trajectory. The company’s pipeline success, especially in biologics for respiratory conditions, along with its strong presence in oncology and cardiovascular treatments, are key drivers for its valuation and long-term earnings profile.
Eli Lilly Experimental Drug Shows Surgery-Level Weight Loss in Phase 3 Trial
Eli Lilly's experimental drug, retatrutide, has demonstrated unprecedented weight loss in Phase 3 clinical trials, achieving an average reduction of 28% over 18 months, which is comparable to bariatric surgery outcomes. This "triple agonist" targets three hormone receptors (GLP-1, GIP, and glucagon), distinguishing it from current GLP-1 therapies. While the drug shows significant promise in treating obesity and related comorbidities, regulatory approval will depend on a thorough review of its safety profile and long-term data.
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins
Compass Pathways is on track to file a New Drug Application for its psilocybin treatment, COMP360, for treatment-resistant depression in Q4, following highly significant Phase 3 results. The company highlights COMP360's rapid efficacy (under 24 hours) and long-lasting durability (up to six months with one or two doses), positioning it as a potentially revolutionary alternative to existing treatments like SPRAVATO. Compass Pathways is also pursuing a rolling FDA submission, preparing for post-approval steps, and sees PTSD as a significant future opportunity.
Dr. Reddy's Laboratories Ltd stock (INE089A01023): recent price action and business overview
Dr. Reddy's Laboratories Ltd shares have recently traded around the ₹1,320 mark on Indian exchanges, reflecting a period of relatively stable activity after a 5-for-1 stock split in late 2024. The company, a prominent global player in generics and specialty pharmaceuticals, generates revenue from generic formulations, active pharmaceutical ingredients, biosimilars, and specialty products across markets like the U.S., India, and Europe. For U.S. investors, Dr. Reddy's offers diversified exposure to the Indian pharmaceutical sector through ADRs, influenced by both international healthcare trends and U.S. regulatory and pricing dynamics.
Revolution Medicines Recasts RAS Story With Phase 3 Win And New Firepower
Revolution Medicines has announced groundbreaking overall survival results from its Phase 3 RASolute 302 trial in metastatic pancreatic cancer, alongside a clinical collaboration with Summit Therapeutics and plans to acquire EQRx, Inc. These developments, which include significant capital infusion, aim to solidify Revolution Medicines' position in RAS-targeted oncology and broaden its therapeutic pipeline. The company's stock, NasdaqGS:RVMD, has seen substantial gains, reflecting investor interest in these strategic moves and clinical milestones despite facing high operating expenses and concentration in RAS-targeted oncology.
AstraZeneca plc stock (GB0009895292): Latest catalyst after recent company news
AstraZeneca plc (GB0009895292) remains a key focus for investors, particularly those in the U.S. seeking global pharmaceutical exposure. The company's performance is driven by its strong portfolio in oncology, cardiovascular, respiratory, and rare diseases, with investor attention centered on clinical trial data, regulatory approvals, and pipeline updates. The article emphasizes AstraZeneca's significance as a bellwether for the broader pharma industry and its potential as a defensive investment during economic uncertainty.
Immutep Faces Class Action Lawsuit; Investors May Claim Losses
Immutep is facing multiple class action lawsuits from law firms including Bragar Eagel & Squire, Rosen Law Firm, Pomerantz LLP, and Bronstein, Gewirtz & Grossman LLC. These lawsuits allege that Immutep made misleading statements and concealed critical data regarding its TACTI-004 clinical trial, which resulted in significant investor losses when the trial was discontinued. Investors who purchased American Depositary Receipts between March 24, 2025, and March 12, 2026, have until July 6, 2026, to apply for lead plaintiff status.
Merck & Co. Inc. stock (US58933Y1055): Keytruda data and Q1 2026 results keep pharma heavyweight in
Merck & Co. Inc. has garnered investor attention due to new clinical data for its cancer drug Keytruda and its first-quarter 2026 financial results. These developments highlight the company's reliance on its oncology franchise, particularly Keytruda, and the importance of its late-stage pipeline for long-term growth. The company's future outlook is significantly influenced by patent timelines, potential biosimilar competition, and drug pricing dynamics, especially in the US market.
Enliven Therapeutics CMO sells $198,971 in stock
Helen Louise Collins, CMO at Enliven Therapeutics (NASDAQ:ELVN), sold 5,000 shares of company stock for $198,971 after exercising stock options. Following these transactions, Ms. Collins directly holds 25,000 shares and 126,268 derivative securities. This comes amidst positive news for Enliven, including updated data from its ENABLE trial and favorable analyst coverage from Guggenheim, H.C. Wainwright, and Clear Street.
Document
Merck & Co., Inc. is offering $6 billion in a mix of floating rate and fixed-rate notes across seven series with varying maturities from 2028 to 2056, to repay borrowings from its recent acquisition of Terns Pharmaceuticals, Inc. While the floating rate notes are not redeemable before maturity, fixed-rate notes can be optionally redeemed by Merck & Co. The notes are unsecured senior debt obligations, ranking equally with other unsecured senior indebtedness.
Merck & Co. Inc. stock (US58933Y1055): Key takeaways from the latest Keytruda growth and pipeline up
Merck & Co. Inc. recently highlighted continued growth for its cancer drug Keytruda and provided an update on its pipeline and 2025 outlook, attracting attention from healthcare investors. The company's core business model focuses on discovering, developing, and marketing innovative medicines, with oncology, vaccines, and animal health products being key revenue drivers. Despite facing industry challenges like patent expirations and pricing pressures, Merck offers US investors exposure to a large-cap healthcare company with global reach.
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
Exelixis (EXEL) has announced a clinical development collaboration with Merck & Co. (MRK) to evaluate its pipeline candidate, zanzalintinib, in combination with subcutaneous Keytruda Qlex for resected stage II/III colorectal cancer. Exelixis will sponsor the phase III STELLAR-316 study, with Merck providing Keytruda. This collaboration, which includes Natera for patient identification, aims to diversify Exelixis's portfolio beyond Cabometyx and further validate the zanzalintinib program.
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors
Merck & Co. Inc. (MRK) stock decreased by 1.09% on Wednesday, closing at $113.00, despite a strong performance by the broader market, with both the S&P 500 and Dow Jones Industrial Average seeing gains. This decline ended a two-day winning streak for Merck. The company's stock underperformed its competitors on this trading day.
Bristol Myers deepens AI investment with Anthropic deal
Bristol Myers Squibb is expanding its use of artificial intelligence by partnering with Anthropic to deploy its Claude AI tool across its operations. The drugmaker intends for Claude to accelerate software and AI development, aid in research, development, and manufacturing, and tap into the company's institutional knowledge. This move follows similar AI investments by other major pharmaceutical companies like Merck, Novo Nordisk, Takeda, and Lilly, highlighting a growing industry trend to leverage AI for more efficient drug discovery and development, despite challenges like data quality and AI "hallucinations."
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion
Pfizer is focusing on its oncology segment for growth, driven by key therapies like Padcev and an expanding pipeline. Oncology sales accounted for 27% of total revenues and grew 7% in Q1 2026, with Padcev showing significant strength and receiving recent FDA approval for metastatic urothelial cancer in combination with Keytruda. The company plans to further expand Padcev's indications, develop new cancer treatments, and leverage its oncology biosimilars, despite competition from other major players like AstraZeneca, Merck, and J&J.
Merck & Co., Inc. stock (US58933Y1055): Key takeaways after latest Keytruda data and Q1 earnings
Merck & Co., Inc. remains a key player in the pharmaceutical industry, with its stock performance closely tied to its dominant cancer drug, Keytruda, its robust pipeline, and the evolving drug pricing environment in the US. Recent first-quarter 2026 earnings and new clinical data for Keytruda highlight the company's strategy to navigate patent expirations and sustain growth through ongoing innovation in oncology and vaccines. The company's large market presence and dividend policy also make it significant for US investors.
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion
Pfizer is focusing on oncology for growth, with oncology
SA News | SEABRIDGE GOLD INC (NYSE:SA)
This article provides recent news and analysis for Seabridge Gold Inc. (NYSE: SA), including its current stock price and links to articles discussing coiled springs and strategic projects in critical mineral supply. The stock recently closed at $29.88, down 2.51%.
Immunovant (NASDAQ: IMVT) shifts to IMVT-1402 with broad late-stage autoimmune program
Immunovant (NASDAQ: IMVT) is re-focusing its entire pipeline on IMVT-1402, a next-generation antibody, due to its positive Phase 1 data showing deep IgG reductions without significant off-target effects. This shift follows the discontinuation of batoclimab after its Phase 3 trials for Thyroid Eye Disease failed to meet primary endpoints. Immunovant plans to advance IMVT-1402 through late-stage clinical trials across six autoimmune indications, including Graves’ disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren’s disease, and cutaneous lupus erythematosus, leveraging prior clinical learnings and aiming for a best-in-class profile with subcutaneous self-administration.
AbbVie stock (US00287Y1091): investors eye Skyrizi and Rinvoq momentum after latest quarterly update
AbbVie's latest quarterly results show a continued transition away from its former blockbuster drug Humira, with significant growth from immunology drugs Skyrizi and Rinvoq, as well as contributions from aesthetics and neuroscience segments. While Humira sales decline, the company's diversified portfolio aims to reshape its earnings profile. Investors are watching its performance amidst regulatory developments and competitive pressures in the pharmaceutical industry.
Sanofi S.A. stock (FR0000120578): diabetes and immunology pipeline in focus after recent updates
Sanofi S.A. has recently shared updates on its diabetes and immunology pipeline, including its blockbuster drug Dupixent and new once-weekly insulin candidates, as it shifts its strategic focus towards higher-growth specialty care drugs and vaccines. The company's performance will depend on its R&D strategy, competitive landscape, and regulatory developments, particularly in the US market, which is a significant revenue driver. Sanofi offers US investors exposure to a diversified pharmaceutical portfolio via its American Depositary Receipts.
Cullen Frost Bankers Inc. Has $22.74 Million Position in Merck & Co., Inc. $MRK
Cullen Frost Bankers Inc. has reduced its stake in Merck & Co., Inc. by 4.2% in the fourth quarter, now holding 215,997 shares valued at approximately $22.74 million. Despite this trimming, institutional ownership in Merck remains strong at 76.07%, with several other firms increasing their positions. Analysts generally rate Merck as a "Moderate Buy" with a consensus target price of $128.18, reflecting a positive outlook on the stock.
Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN
Fideuram Intesa Sanpaolo Private Banking S.P.A. has initiated a new position in Regeneron Pharmaceuticals, Inc. by purchasing 23,047 shares valued at approximately $17.8 million during the fourth quarter. This move comes despite recent pressure on Regeneron due to a failed late-stage melanoma trial, though the company did report strong Q1 results with revenue up 19% year-over-year and beating EPS estimates. Analysts maintain a "Moderate Buy" rating for REGN with an average price target of $792.65, indicating potential upside.
Exelixis EVP and CFO Senner sells $1.75m in company stock
Christopher J. Senner, EVP and CFO of Exelixis, Inc. (NASDAQ:EXEL), sold 34,901 shares of company stock for $1.75 million on May 18, 2026. This sale occurred while the stock is near its 52-week high, although InvestingPro analysis suggests it remains undervalued. Senner also had shares withheld for tax obligations related to vested restricted stock units.
Merck Completes Acquisition of Terns Pharmaceuticals
Merck & Co Inc. has successfully acquired Terns Pharmaceuticals Inc., reinforcing its hematology and oncology pipeline. The acquisition primarily focuses on TERN-701, a promising CML therapy candidate with FDA Breakthrough Therapy Designation, which is expected to strengthen Merck's long-term oncology growth despite an anticipated near-term earnings charge of approximately US$2.35 per share in 2026. This strategic move aims to diversify Merck's portfolio beyond existing blockbuster assets and address unmet needs in chronic myeloid leukemia treatment.
Merck & Co. Inc. stock (US58933Y1055): Key takeaways after latest Keytruda data and oncology updates
Merck & Co. Inc. has published new clinical data for its cancer drug Keytruda and other oncology assets, reinforcing its focus on its oncology strategy. Keytruda, along with vaccines and pipeline candidates, forms the core drivers of the US pharmaceutical giant's revenue and future growth. Investors should monitor the company's clinical updates and R&D investments, as it prepares for future patent expirations.
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Novo Nordisk and Eli Lilly, dominant in the GLP-1 weight loss market, are aggressively expanding their reach beyond the U.S. into global markets, driven by high demand and the need for diversification. This global expansion, supported by new clinical data for their latest weight-loss pills, is expected to significantly boost the obesity treatment market, projected to reach $190 billion by 2035. The article highlights thematic ETFs like Tema Heart & Health ETF (HRTS), Roundhill GLP-1 & Weight Loss ETF (OZEM), and Amplify Weight Loss Drug & Treatment ETF (THNR) as compelling investment opportunities for diversified exposure to this growing sector.
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Exelixis has entered a clinical development collaboration with Merck for the Phase 3 STELLAR-316 pivotal trial, which will evaluate zanzalintinib with and without KEYTRUDA QLEX in patients with resected stage II/III colorectal cancer. Merck will supply KEYTRUDA QLEX for the trial, which aims to prevent or delay metastatic progression in MRD+ patients. Exelixis plans to initiate the trial in mid-2026, leveraging Natera's Signatera™ assay to identify eligible patients.
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Exelixis has announced a clinical development collaboration with Merck for the STELLAR-316 Phase 3 pivotal trial. This trial will evaluate zanzalintinib in combination with Merck's KEYTRUDA QLEX™ for patients with resected stage II/III colorectal cancer. Under the agreement, Exelixis will sponsor the trial while Merck supplies KEYTRUDA QLEX™, aiming to potentially prevent or delay metastatic progression in this high-risk patient population.
Merck & Co., Inc. stock (US58933Y1055): Key takeaways after the latest Keytruda and Gardasil updates
Merck & Co., Inc. remains a key player in global pharmaceuticals, with its stock influenced by the continued success of its blockbuster drugs Keytruda and Gardasil, the progress of its broader pipeline, and ongoing policy discussions around US drug pricing. While the company's oncology and vaccine franchises present significant potential, they also highlight a concentration risk, which is somewhat balanced by the diversification provided by its animal health and other human health products. Investors will closely monitor Merck's future data readouts, regulatory milestones, and guidance updates to assess how the company navigates patent expirations, market competition, and evolving healthcare policies.
Press Release: Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Immunic, Inc. has announced the appointment of Michael W. Bonney as the new Chair of its Board of Directors. Bonney brings extensive experience from his roles at MedImmune and Cubist Pharmaceuticals, and currently serves on the boards of Alexion Pharmaceuticals and Magenta Therapeutics. His appointment is expected to provide strategic leadership as Immunic advances its clinical programs.
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
The global Cell Culture Media Market is projected to grow from USD 3.7 billion in 2026 to USD 7.1 billion by 2036, driven by rising biologics production, expanding cell and gene therapy pipelines, and increasing adoption of serum-free formulations. Key players like Avantor, Thermo Fisher Scientific, and Lonza Group AG are focusing on scalable GMP production and advanced media platforms to meet demand. The serum-free media segment and cancer research application are expected to lead market growth, with China, Japan, and Germany showing the fastest regional expansion.
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
Immunic, Inc. has announced the appointment of Michael W. Bonney as the Chair of its Board of Directors, effective May 16, 2026. Bonney brings over 30 years of biopharmaceutical leadership experience, including pivotal roles in the commercialization of Avonex® for Multiple Sclerosis during his time at Biogen and serving as CEO of Cubist Pharmaceuticals. His appointment comes at a critical time for Immunic as it advances its lead development program, vidofludimus calcium, through phase 3 clinical trials for relapsing MS.
